Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160519 | 0.86 | CHRM1 (0.46) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL16426283 | 0.86 | CHRM1 (0.46) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL572790 | 0.86 | CA2 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1300693 | 0.84 | CHRM1 (0.44) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL30402703 | 0.84 | CA2 (0.48) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL28763210 | 0.84 | CA2 (0.48) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL25499442 | 0.84 | CHRM1 (0.44) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5501616 | 0.84 | GPR84 (0.52) | SLC1A2SLC1A1GRIK1GRIK2CA2 | |
| SCHEMBL28586731 | 0.84 | CHRM1 (0.44) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL27510687 | 0.84 | CA2 (0.48) | TDP1CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-118344719-B | Carbon fiber composite material applied to bicycle frame and preparation method thereof | 惠州市德泰士达科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118344719-A | Carbon fiber composite material applied to bicycle frame and preparation method thereof | 惠州市德泰士达科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117916245-A | Pyrimidine ring compound and preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024061370-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2024-03-28 | — | — | WO | disclosed |
| WO-2024022471-A1 | KRAS INHIBITOR COMPOUND | 上海湃隆生物科技有限公司 | 2024-02-01 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230296984-A1 | EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-09-21 | — | — | US | disclosed |
| CN-110248949-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-4107166-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-8367251-B2 | Anode with lithium containing ionic polymer coat, method of manufacturing same, secondary battery, and method of manufacturing same | SONY CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8226773-B2 | Method and composition for cleaning wafers | FONTANA TECHNOLOGY (US) | 2012-07-24 | — | — | US | disclosed |
| CN-102395579-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2012-03-28 | — | — | CN | disclosed |
| CN-101568536-B | 2-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-12-28 | — | — | CN | disclosed |
| US-7959739-B2 | Particle removal cleaning method and composition | FONTANA TECHNOLOGY (US) | 2011-06-14 | — | — | US | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
| CN-101568536-A | 2-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-28 | — | — | CN | disclosed |
| US-20090151755-A1 | Method and Composition for Cleaning Wafers | FONTANA TECHNOLOGY | 2009-06-18 | — | — | US | disclosed |
| US-20090149364-A1 | Particle Removal Cleaning Method and Composition | FONTANA TECHNOLOGY | 2009-06-11 | — | — | US | disclosed |
| US-20090061325-A1 | ANODE, METHOD OF MANUFACTURING SAME, SECONDARY BATTERY, AND METHOD OF MANUFACTURING SAME | SONY CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | CFD, CFH, TFPI | TDP1 2691/4885CHRM1 4868/4885AKR1A1 1969/4885 |
| US-20090149364-A1 | Particle Removal Cleaning Method and Composition | SPOUT1, EMG1, SRM | TDP1 1580/4885CHRM1 1983/4885AKR1A1 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.